Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03860519
Recruitment Status : Recruiting
First Posted : March 4, 2019
Last Update Posted : March 4, 2019
Sponsor:
Information provided by (Responsible Party):
Giselle Mosnaim, NorthShore University HealthSystem

Tracking Information
First Submitted Date  ICMJE September 26, 2018
First Posted Date  ICMJE March 4, 2019
Last Update Posted Date March 4, 2019
Actual Study Start Date  ICMJE March 7, 2018
Estimated Primary Completion Date July 1, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 28, 2019)
Change in Short Acting Bronchodilator Medication use in Group with Propeller Health Platform Digital Technology Turned On vs Group with Propeller Health Platform Digital Technology Turned Off [ Time Frame: 3.5 months ]
Use of the Propeller Health Platform in the treatment group in active mode, compared to the attention control group in silent mode, will demonstrate a 20% change in SABA use and/or minimal clinically important difference (three points) change on the ACT and/or change from ACT score ≤ 19 to ≥20, at 3-months. The 20% change in SABA use = 20 point change (e.g. if a participants uses SABA 40% of days over the 2 week run-in period, and they change SABA use to 20% of days during the final 14 days of the active treatment period, that will equal a 20 point change. If SABA use changes from 40% of days over the 2- week run-in period to 32% of days during the final 14 days of the active treatment period, this will not be considered a 20 point change).
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2019)
  • Participant and clinician satisfaction as assessed by brief post-study survey of Propeller Health Platform Digital Technology [ Time Frame: 3.5 months ]
    Study staff developed a brief survey using open-ended questions (i.e. 20 questions, no scales used, no minimum or maximum scores are applicable) to ask participants and clinicians whether they were satisfied using the Propeller Health Platform Digital Technology. Standardized instruments are not being used.
  • Inhaled Corticosteroid Medication taking Behavior in the Group using Propeller Health Platform Digital Technology Turned On vs Group using Propeller Health Platform Digital Technology Turned Off [ Time Frame: 3 months ]
    To determine if two Propeller Health Platform Digital Technology arms (i.e. Arm #1= Technology in active "on" mode and Arm #2= Technology in passive "off" mode) demonstrate a change in inhaled corticosteroid medication taking behavior at 3 months.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma
Official Title  ICMJE The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma (Propeller Health)
Brief Summary This is a behavioral randomized controlled trial of adults with uncontrolled persistent asthma that tests if the Propeller Health sensor, mobile application, and dashboard can improve adherence to ICS.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Behavioral: Electronic Medication Monitors on ICS and SABA - Active Mode
    The patients in the intervention group will have sensors that are "active", so that these patients receive reminders about when to use their inhalers medications.
    Other Name: MDI, Diskus
  • Behavioral: Electronic Medication Monitors on ICS and SABA - Silent Mode
    The patients in the control group will have sensors that are "silent", so that these patients do not receive reminders about when to use their inhalers medications.
    Other Name: MDI, Diskus
  • Behavioral: Asthma App Tracking of ICS/SABA Usage - Active Mode
    Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
  • Behavioral: Asthma App Tracking of ICS/SABA Usage - Silent Mode
    Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
  • Behavioral: NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes
    Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
  • Behavioral: NorthShore Connect Real Time ICS and SABA Usage Feedback - No
    Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
  • Behavioral: Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes
    Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
  • Behavioral: Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No
    Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
Study Arms  ICMJE
  • Experimental: Intervention Group
    The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has "poor adherence" ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR "at risk" alerts if a patient transitions to a "not well controlled" or "poorly controlled" status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard).
    Interventions:
    • Behavioral: Electronic Medication Monitors on ICS and SABA - Active Mode
    • Behavioral: Asthma App Tracking of ICS/SABA Usage - Active Mode
    • Behavioral: NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes
    • Behavioral: Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes
  • Experimental: Control Group
    The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
    Interventions:
    • Behavioral: Electronic Medication Monitors on ICS and SABA - Silent Mode
    • Behavioral: Asthma App Tracking of ICS/SABA Usage - Silent Mode
    • Behavioral: NorthShore Connect Real Time ICS and SABA Usage Feedback - No
    • Behavioral: Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 28, 2019)
100
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 30, 2019
Estimated Primary Completion Date July 1, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Under the care of a staff asthma physician (i.e. pulmonologist or allergist/immunologist) at NorthShore University HealthSystem (NS)
  • Have an active NorthShore Connect (patient portal) account
  • Persistent uncontrolled asthma in the past 12 months
  • Active prescription for daily ICS medication for asthma

Exclusion Criteria:

  • candidate refusal
  • the presence of other co-morbidities (e.g. severe psychiatric disorder) that could interfere with study participation
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 25 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Brittney Adams, BS 224-364-7459 badams@northshore.org
Contact: Candy Gonzalez, BA 224-364-7456 cgonzalez@northshore.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03860519
Other Study ID Numbers  ICMJE EH17-322
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Giselle Mosnaim, NorthShore University HealthSystem
Study Sponsor  ICMJE NorthShore University HealthSystem
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Giselle Mosnaim, MD NorthShore University HealthSystem
PRS Account NorthShore University HealthSystem
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP